InflaRx N.V. (IFRX) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, InflaRx N.V. (NASDAQ: IFRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $1.72 (-0.87% 1D, market cap $252.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IFRX ranks #233 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IFRX carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVMN (Evommune Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $247.1M) and ELDN (Eledon Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $247.0M). Among the 5-stock peer group, IFRX leads on earnings multiple (N/A) while EVMN leads on capital efficiency (-35.0% ROIC).
For InflaRx N.V. (IFRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #233 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 49.2 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 58/100 (D+) score, IFRX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.87) or 200D SMA ($1.64) invalidates the momentum regime and cuts Target Base ($1.72) toward Bear Floor ($1.34).
InflaRx N.V. (IFRX) slipped -0.87% to $1.72, trading at 43% of its 52-week range ($0.8 – $2.95). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 (G
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IFRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IFRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, InflaRx N.V. (IFRX) ranks #233 by composite RQD confidence (58/100, grade D+) and #545 by equity capitalization ($252.7M). Within this direct 5-issuer industry benchmark cohort, IFRX leads on earnings valuation at N/A trailing P/E, while EVMN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IFRX currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IFRX
ACTIVE
InflaRx N.V. | D+ | 58/100 | — | — | — | -0.87% | $252.7M | Benchmark Subject |
| EVMN Evommune Inc. | D- | 43/100 | — | — | -35.0% | +7.92% | $247.1M | /evmn-vs-ifrx → |
| ELDN Eledon Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +10.15% | $247.0M | /eldn-vs-ifrx → |
| LFCR Lifecore Biomedical Inc. | D | 51/100 | — | — | — | +0.15% | $246.8M | /lfcr-vs-ifrx → |
| IMRX Immuneering Corporation (Class A) | D | 45/100 | — | — | -35.0% | +0.75% | $260.1M | /imrx-vs-ifrx → |
InflaRx N.V. (IFRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $252.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, InflaRx N.V. (NASDAQ: IFRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $1.72 (-0.87% 1D, market cap $252.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IFRX ranks #233 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IFRX carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVMN (Evommune Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $247.1M) and ELDN (Eledon Pharmaceuticals Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $247.0M). Among the 5-stock peer group, IFRX leads on earnings multiple (N/A) while EVMN leads on capital efficiency (-35.0% ROIC).
For InflaRx N.V. (IFRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #233 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
IFRX last traded at $1.72 (-0.87% on volume of 306,544 shares), positioning the stock -8.02% below its 50-day simple moving average ($1.87) and +4.88% above its 200-day simple moving average ($1.64). Across its 52-week range of $0.80 to $2.95, IFRX sits at the 42.8% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.51 to $1.93).
Why IFRX Stock slipped -0.87% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).